Alpha Cognition Inc
ACOG
Clasificación en acciones
#20048
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Precio por acción
$8.63
Última sincronización: 2026-10-21
Capitalización bursátil
$134.04M
Cambio (1 día)
0.23%
Cambio (1 año)
71.57%
País
US
Comercio Alpha Cognition Inc (ACOG)
Categoría
Healthcare
Historial del precio de la acción de Alpha Cognition Inc (ACOG)
Precio más alto de cierre: $5.46 el 2024-12-01
Precio más bajo de cierre: $18.75 el 2021-06-01
Precio más bajo de cierre: $18.75 el 2021-06-01
Historial del precio de la acción de Alpha Cognition Inc desde 2021 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.40 | -4.08% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
